IAVI

Pipeline

IAVI-supported candidates

Below is a list of candidates that IAVI is supporting. To see IAVI-led candidates, visit our main pipeline page. For an explanation of development phases, visit our clinical development page.

Pipeline: IAVI-led candidates

HIV vaccine candidates

HIV
Candidate name

BG505 GT1.1 gp140, adjuvanted (AS01B)

HIV

Partners

Amsterdam UMC; George Washington University; GlaxoSmithKline; Rockefeller University

Phase 1
Clinical trial info
Candidate name

BG505 SOSIP gp140, adjuvanted (3M-052 AF + alum) — IAVI C107

HIV

Partners

Access to Advanced Health Institute; National Institute of Allergy and Infectious Diseases

Phase 1
Clinical trial info
Candidate name

BG505 SOSIP gp140, adjuvanted (3M-052 AF + alum) — IAVI C110

HIV

Partners

3M; Access to Advanced Health Institute; Polymun Scientific GmbH

Phase 1
Clinical trial info
Candidate name

DNA-HIV-PT123, AIDSVAX®B/E; DNA-HIV-PT123, CN54gp140, MVA CMDR,CN54gp140; TAF/FTC; TDF/FTC

HIV

Partners

Centre Hospitalier Universitaire Vaudois; CONRAD; EuroVacc Foundation; Gilead Sciences; IAVI; Imperial College London; Instituto Nacional de Saúde, Mozambique; Karolinska Institutet; King’s College London; Ludwig-Maximilians – University of Munich; Medical Research Council, South Africa; Muhimbili University of Health and Allied Sciences; National Institute for Medical Research, Tanzania; University College, London

Phase 1
Clinical trial info
Candidate name

GRAd networked T-cell epitope

HIV

Partners

Africa Health Research Institute; Bill & Melinda Gates Foundation; Collaboration for AIDS Vaccine Discovery Vaccine Immunology Statistical Center; Desmond Tutu Health Foundation; Fred Hutchinson Cancer Center; IAVI; Mutala Trust; Ragon Institute; ReiThera SRL; The National Institute for Communicable Diseases of South Africa

Pre-clinical
Candidate name

MosM3.1, MosM3.2, MosM3.3, adjuvanted

HIV

Partners

Polymun Scientific GmbH

Phase 1
Clinical trial info

Tuberculosis (TB) vaccine candidates

Tuberculosis
Candidate name

MTBVAC (People living with and without HIV)

Tuberculosis

Partners

Biofabri S.L., HIV Vaccine Trials Network; National Institute of Allergy and Infectious Diseases; South African Tuberculosis Vaccine Initiative; Universidad de Zaragoza

Phase 2
Clinical trial info

Mini-protein for COVID-19 prophylaxis

COVID-19
Candidate name

IPD-52520

COVID-19

Partners

Bill & Melinda Gates Foundation; Institute for Protein Design; SK bioscience

Pre-clinical